Costs of asthma are correlated with severity: a 1-yr prospective study.
about
How cytokines co-occur across asthma patients: from bipartite network analysis to a molecular-based classificationBronchial thermoplasty in asthma: current perspectivesMeteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy OrganizationStrategies for molecular classification of asthma using bipartite network analysis of cytokine expressionReslizumab for Poorly Controlled, Eosinophilic AsthmaImpact of Age and Sex on Outcomes and Hospital Cost of Acute Asthma in the United States, 2011-2012Predictors of asthma exacerbation among patients with poorly controlled asthma despite inhaled corticosteroid treatment.Asthma Is More Severe in Older Adults.Obstructive Sleep Apnea Risk, Asthma Burden, and Lower Airway Inflammation in Adults in the Severe Asthma Research Program (SARP) II.Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research ProgramSevere Asthma in Children: Insights from the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.Predicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines.Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a reviewEvaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR study.Economic burden of asthma: a systematic reviewThe role of omalizumab in the treatment of severe allergic asthma.Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial.Bronchial thermoplasty: a novel technique in the treatment of severe asthma.Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study.Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines.Recommendation for optimal management of severe refractory asthma.Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting.The association between asthma control, health care costs, and quality of life in France and SpainWeekly low-dose methotrexate for reduction of Global Initiative for Asthma Step 5 treatment in severe refractory asthma: study protocol for a randomized controlled trialNew therapies and management strategies in the treatment of asthma: patient-focused developments.Randomised evaluation of the Italian medicines use review provided by community pharmacists using asthma as a model (RE I-MUR).Analysis of a Panel of 48 Cytokines in BAL Fluids Specifically Identifies IL-8 Levels as the Only Cytokine that Distinguishes Controlled Asthma from Uncontrolled Asthma, and Correlates Inversely with FEV1Severe asthma in children.Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD.A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthmaTrends in the use of antiasthmatic medications in Morocco (1999-2010)Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations.The differentiation of chronic obstructive pulmonary disease from asthma: a review of current diagnostic and treatment recommendations.An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.The Clinical and Health Economic Value of Clinical Laboratory DiagnosticsAsthma costs and social impact.Asthma in pediatric patients: unmet need and therapeutic options.Monoclonal antibodies for the treatment of severe asthma.Asthma and risk of lung cancer.
P2860
Q23921988-E3F1C9F0-5770-49E3-ACD5-069E0326EBBAQ26852643-9925D82B-38D6-4649-9C54-662905D4B25FQ28383187-DBAACCED-ABFD-462D-B6CD-E5787BC03E9CQ28394447-D8453E3D-8550-4CBF-8C61-D8C2B6F6818BQ29040017-8515865D-AA10-46FB-89A3-D9217310E62EQ30276625-F9AF920D-EC69-4E35-9799-8C7F477DA923Q30277850-F0829021-00B7-4540-B786-1A3CD1B2EE2FQ30278970-F15A5A6D-452D-4CD1-9678-9BDBB8F7C6BBQ30279308-3EDB3076-6229-41EE-BAE7-18C21EBBF5C9Q30428546-7B1F2A1B-F927-4A13-838B-EFA6A015EC4AQ30431432-20119364-DAB1-4921-BF6E-66752E706163Q30433497-6B184723-4934-4D0F-B591-D400D3D73702Q30801642-4B069F24-24EC-41C0-81F7-ADDC6AC2D1ABQ31142264-6EE54EC9-D1D2-44C4-840D-70CECDD634DDQ33447966-6C6C29B7-7E57-41B3-81D1-94A9464AF91CQ33591890-BFAE88FE-EDC1-43FE-90A4-403BC4B39798Q33725032-C1594042-E63F-4FB0-8102-3E6464D2247EQ33818701-7394DB35-19CB-42E6-AF1D-1907A36C9ADBQ34113269-0A37CA4D-C192-43CE-9293-50F9CBA873E4Q34253605-0742486D-58DD-4924-B59F-23D42BE70766Q34483166-6E520880-65A4-4BC1-A079-24E24F7AEFA7Q34620187-F617644B-60C6-4071-B967-79C60367B8CEQ34627039-09E83709-07F8-44A0-9BB0-C3DF538C7438Q34630944-3F19FA03-5E68-4568-BED9-F8074830ECE1Q34996190-157AE2AC-B552-44E0-96DB-F16EF7FD6CF9Q35025262-1A71E890-2342-4168-B04B-D1448D1F2D38Q35576342-9220C1BB-522A-40F0-B1FA-082E5E1A6F7CQ35642196-5921B393-EB3C-497A-A080-E864797244AAQ36108246-7E39D5F2-F311-4572-B9C6-DF3EA8D9FF93Q36428054-5E125F50-3D97-401E-BD42-7D3238956F5FQ36642971-E7F1A5B2-34CE-4F5B-AFF9-7543D33D1261Q36695205-17827EAB-77E2-42BD-A941-0274E46C233FQ36825039-9E45EAED-4717-4ADA-8A11-4604C7752CF3Q36924669-5C988796-4E41-4BD3-92D1-0AE8A7FE46D9Q37150465-48587542-C76C-46A9-8C23-57C2BBB3A41DQ37155167-5997E47E-18CD-4F48-A000-2D71292720CDQ37569596-5AB27456-892F-4943-9194-2989CC678F46Q37781216-32BA5680-E429-473B-83C5-84D0CF766977Q37848219-7CE3F27A-B287-4850-A588-1DA6AAD05C02Q37942737-0203D646-5C2D-4569-A61A-3824C2A5ED1C
P2860
Costs of asthma are correlated with severity: a 1-yr prospective study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Costs of asthma are correlated with severity: a 1-yr prospective study.
@en
Costs of asthma are correlated with severity: a 1-yr prospective study.
@nl
type
label
Costs of asthma are correlated with severity: a 1-yr prospective study.
@en
Costs of asthma are correlated with severity: a 1-yr prospective study.
@nl
prefLabel
Costs of asthma are correlated with severity: a 1-yr prospective study.
@en
Costs of asthma are correlated with severity: a 1-yr prospective study.
@nl
P2093
P1476
Costs of asthma are correlated with severity: a 1-yr prospective study.
@en
P2093
P356
10.1183/09031936.02.00232001
P577
2002-01-01T00:00:00Z